234 related articles for article (PubMed ID: 19182832)
1. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.
Tse WT; Duerst R; Schneiderman J; Chaudhury S; Jacobsohn D; Kletzel M
Bone Marrow Transplant; 2009 Aug; 44(3):145-56. PubMed ID: 19182832
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
[TBL] [Abstract][Full Text] [Related]
4. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
7. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.
Ward J; Kletzel M; Duerst R; Fuleihan R; Chaudhury S; Schneiderman J; Tse WT
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1612-21. PubMed ID: 26025482
[TBL] [Abstract][Full Text] [Related]
8. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
9. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
[TBL] [Abstract][Full Text] [Related]
11. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
12. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
[TBL] [Abstract][Full Text] [Related]
13. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
[TBL] [Abstract][Full Text] [Related]
14. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
[TBL] [Abstract][Full Text] [Related]
15. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Freytes CO; Toro JJ; Yeh RF; Stadtmauer EA; Ratanatharathorn V; Akpek G; Sahovic E; Tricot GJ; Shaughnessy PJ; White DJ; Rodriguez TE; Solomon SR; Yu LH; Zhao C; Patil S; Armstrong E; Smith A; Elekes A; Kato K; Reece DE
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1949-57. PubMed ID: 25139216
[TBL] [Abstract][Full Text] [Related]
17. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
Beri R; Chunduri S; Sweiss K; Peace DJ; Mactal-Haaf C; Dobogai LC; Shord S; Quigley JG; Chen YH; Mahmud N; Rondelli D
Bone Marrow Transplant; 2010 Feb; 45(2):249-53. PubMed ID: 19543331
[TBL] [Abstract][Full Text] [Related]
18. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
19. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
Bone Marrow Transplant; 2008 Apr; 41(7):621-5. PubMed ID: 18084338
[TBL] [Abstract][Full Text] [Related]
20. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
